Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Accumulated Expenses (2019 - 2026)

Aytu Biopharma has reported Other Accumulated Expenses over the past 7 years, most recently at $2.9 million for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 58.88% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, down 58.88% year-over-year, with the annual reading at $3.4 million for FY2025, 47.23% up from the prior year.
  • Other Accumulated Expenses was $2.9 million for Q4 2025 at Aytu Biopharma, up from $2.0 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $9.1 million in Q1 2024 and troughed at $1.8 million in Q1 2025.
  • The 5-year median for Other Accumulated Expenses is $3.5 million (2022), against an average of $4.8 million.
  • Year-over-year, Other Accumulated Expenses surged 2549.84% in 2021 and then plummeted 79.79% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $3.2 million in 2021, then rose by 15.35% to $3.7 million in 2022, then tumbled by 30.87% to $2.5 million in 2023, then surged by 180.95% to $7.1 million in 2024, then plummeted by 58.88% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Other Accumulated Expenses are $2.9 million (Q4 2025), $2.0 million (Q3 2025), and $3.4 million (Q2 2025).